Acorda Therapeutics reports company developments tied to neurological therapies, product commercialization, and operating results. Recurring updates cover INBRIJA revenue and commercialization, AMPYRA sales, FAMPYRA rights and international arrangements, and the company’s ARCUS inhaled delivery technology.
Acorda news also includes quarterly and year-end financial-result announcements, webcast notices, material agreements, capital-structure disclosures, governance matters, and clinical or regulatory disclosures connected to its Parkinson’s disease and multiple sclerosis therapy portfolio.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.